<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808819</url>
  </required_header>
  <id_info>
    <org_study_id>D3250C00037</org_study_id>
    <nct_id>NCT02808819</nct_id>
  </id_info>
  <brief_title>A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist</brief_title>
  <acronym>MELTEMI</acronym>
  <official_title>A Multicenter, Open-label, Safety Extension Study With Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to continue to characterize the safety profile of benralizumab&#xD;
      administration and monitor the pharmacodynamic activity of the drug in those asthma patients&#xD;
      who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor&#xD;
      study D3250C00021 (BORA, NCT02258542).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label safety extension study designed to evaluate the safety and tolerability&#xD;
      of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) in severe asthma&#xD;
      patients on inhaled corticosteroid and long-acting β2 agonist (ICS-LABA) therapy with or&#xD;
      without chronic oral corticosteroids (OCS) and/or other asthma controllers. All patients will&#xD;
      receive active drug on the same dosing regimen they received in BORA (NCT02258542). In order&#xD;
      to protect the blind of BORA, patients will remain blinded to treatment regimen allocation&#xD;
      until they have completed all end of treatment (EOT) assessments in BORA and signed informed&#xD;
      consent for participation in this study, after which treatment allocation will be unblinded&#xD;
      to both the investigator and the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Basophils, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Basophils.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Leukocytes, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Leukocytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Lymphocytes, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Lymphocytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neutrophils, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Neutrophils.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Monocytes, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Monocytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Platelets, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Platelets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Hematocrit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Erythrocytes, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Erythrocytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in hematologic lab parameter of Hemoglobin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in chemistry test ALT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in chemistry test AST.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bilirubin, Full Analysis Set</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from baseline in chemistry test Bilirubin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Asthma Exacerbations During Study Period</measure>
    <time_frame>From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented.</time_frame>
    <description>Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period</measure>
    <time_frame>From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented.</time_frame>
    <description>Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Blood Eosinophils Count</measure>
    <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
    <description>Change from Baseline to End of Treatment in blood eosinophils count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study</measure>
    <time_frame>From week 0 to week 184 in study treatment period and plus 12 weeks follow up period</time_frame>
    <description>Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Exposure</measure>
    <time_frame>From week 0 to week 184 in study treatment period</time_frame>
    <description>Duration of exposure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">447</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Benralizumab administered subcutaneously every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Benralizumab administered subcutaneously every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab administered subcutaneously every 4 weeks</description>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab administered subcutaneously every 8 weeks</description>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent for study participation must be obtained prior to any study related&#xD;
             procedures being performed and according to international guidelines and/or applicable&#xD;
             European Union guidelines.&#xD;
&#xD;
          -  Female and male patients who have completed at least 16 and not more than 40 weeks in&#xD;
             Study D3250C00021.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must agree to use an effective form of birth&#xD;
             control throughout the study duration and for 16 weeks after the last dose of&#xD;
             Investigational Product (IP)&#xD;
&#xD;
          -  For WOCBP only: Have a negative urine pregnancy test prior to administration of IP at&#xD;
             Visit 1.&#xD;
&#xD;
          -  All male patients who are sexually active must agree to use a double barrier method of&#xD;
             contraception (condom with spermicide) from the first dose of IP until 16 weeks after&#xD;
             their last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic,&#xD;
             renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological,&#xD;
             psychiatric or major physical impairment that is not stable in the opinion of the&#xD;
             Investigator and could:&#xD;
&#xD;
               -  Affect the safety of the patient throughout the study&#xD;
&#xD;
               -  Influence the findings of the study or their interpretations&#xD;
&#xD;
               -  Impede the patient's ability to complete the entire duration of study&#xD;
&#xD;
          -  A helminth parasitic infection diagnosed during a predecessor study that has either&#xD;
             required hospitalization, has not been treated, has been incompletely treated or has&#xD;
             failed to respond to standard of care therapy&#xD;
&#xD;
          -  Any clinically significant change in physical examination, vital signs, ECG,&#xD;
             hematology, clinical chemistry, or urinalysis during the predecessor study which in&#xD;
             the opinion of the investigator may put the patient at risk because of his/her&#xD;
             participation in the study, or may influence the results of the study, or interfere&#xD;
             with the patient's ability to complete the entire duration of the study&#xD;
&#xD;
          -  Current malignancy or malignancy that developed during the predecessor study (subjects&#xD;
             that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was&#xD;
             resected for cure, or in situ carcinoma of the cervix that has been treated/cured will&#xD;
             not be excluded).&#xD;
&#xD;
          -  Receipt of live attenuated vaccines within 30 days prior to initiation of treatment in&#xD;
             this study, during the treatment period, and for 16 weeks (5 half-lives) after the&#xD;
             last dose of the IP&#xD;
&#xD;
          -  Receipt of immunoglobulin or blood products within 30 days prior to Visit 1&#xD;
&#xD;
          -  Planned major surgical procedures during the conduct of the study&#xD;
&#xD;
          -  Previous participation in the present study&#xD;
&#xD;
          -  Concurrent enrolment in another drug-related interventional clinical trial&#xD;
&#xD;
          -  AstraZeneca staff involved in the planning and/or conduct of the study&#xD;
&#xD;
          -  Employees of the study center or any other individuals involved with the conduct of&#xD;
             the study or immediate family members of such individuals&#xD;
&#xD;
          -  Patients with important protocol deviations in the predecessor study at the discretion&#xD;
             of the Sponsor&#xD;
&#xD;
          -  Patients with ongoing serious adverse events (SAEs) from the prior study should not be&#xD;
             enrolled into the this extension study until the SAE has resolved&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsboro</city>
        <state>Alabama</state>
        <zip>35768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodland</city>
        <state>California</state>
        <zip>95695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hodges</city>
        <state>South Carolina</state>
        <zip>29653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aire</city>
        <zip>C1121 ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Plata</city>
        <zip>B1902COS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500GIP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankston</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrich</city>
        <zip>2850</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <zip>T8L 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quillota</city>
        <zip>2260000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talcahuano</city>
        <zip>4270918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 17</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <zip>337 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Mans Cedex</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geesthacht</city>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>20927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>D-30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aleksandrów Łódzki</city>
        <zip>95-070</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dobre Miasto</city>
        <zip>11-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorzów Wlkp</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kościan</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubin</city>
        <zip>59-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-552</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrów Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <zip>32-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Slaska</city>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-205</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sosnowiec</city>
        <zip>41-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wieluń</city>
        <zip>98-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wołomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>91-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Żnin</city>
        <zip>88-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <zip>362007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagunto(Valencia)</city>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv Region</city>
        <zip>61022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv Region</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv Region</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv Region</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <zip>4300</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chertsey</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Peru</country>
    <country>Philippines</country>
  </removed_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3250C00037&amp;amp;attachmentIdentifier=c52ffe9a-53b4-40d3-935b-1b8ecf80bc07&amp;amp;fileName=d3250c00037-revised-csp-2-redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>CSP redacted.</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3250C00037&amp;amp;attachmentIdentifier=d7b2554d-b014-4ffa-adec-c930fc06f4f5&amp;amp;fileName=d3250c00037-sap-ed-2-redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>SAP redacted.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <results_first_submitted>February 12, 2021</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Bronchial Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Obstructive Lung Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02808819/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02808819/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>447 patients enrolled in MELTEMI, 1 patient from Czech Republic was not treated, thus 446 patients received at least 1 dose of IP. Among these treated participants, 347 were from studies SIROCCO(NCT01928771)/CALIMA(NCT01914757) and 99 were from study ZONDA(NCT02075255).</recruitment_details>
      <pre_assignment_details>170 participants from SIROCCO(NCT01928771)/CALIMA(NCT01914757) assigned to Benralizumab 30 mg every 4 weeks (q4w) with 1 participant not treated. 178 participants from SIROCCO/CALIMA received Benralizumab every 8 weeks (q8w). 51 participants from ZONDA(NCT02075255) received Benralizumab q4w. 48 participants from study ZONDA received Benralizumab q8w.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benra 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Benra 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>eg. no treatment efficacy on asthma</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of study-specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set is defined to include subjects who received at least 1 dose of investigational product (IP).</population>
      <group_list>
        <group group_id="B1">
          <title>Benra 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Benra 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="446"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="12.00"/>
                    <measurement group_id="B2" value="53.0" spread="11.64"/>
                    <measurement group_id="B3" value="53.2" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Basophils, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Basophils.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Basophils.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.0229"/>
                    <measurement group_id="O2" value="0.012" spread="0.0243"/>
                    <measurement group_id="O3" value="0.013" spread="0.0236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Leukocytes, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Leukocytes.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leukocytes, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Leukocytes.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.254" spread="2.0446"/>
                    <measurement group_id="O2" value="-0.498" spread="1.7217"/>
                    <measurement group_id="O3" value="-0.377" spread="1.8896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Lymphocytes, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Lymphocytes.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lymphocytes, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Lymphocytes.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.098" spread="0.5479"/>
                    <measurement group_id="O2" value="-0.142" spread="0.6544"/>
                    <measurement group_id="O3" value="-0.121" spread="0.6038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neutrophils, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Neutrophils.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neutrophils, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Neutrophils.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.237" spread="1.8765"/>
                    <measurement group_id="O2" value="-0.392" spread="1.4802"/>
                    <measurement group_id="O3" value="-0.315" spread="1.6866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Monocytes, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Monocytes.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monocytes, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Monocytes.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.1835"/>
                    <measurement group_id="O2" value="0.056" spread="0.1766"/>
                    <measurement group_id="O3" value="0.055" spread="0.1798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Platelets, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Platelets.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelets, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Platelets.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="41.72"/>
                    <measurement group_id="O2" value="11.9" spread="36.13"/>
                    <measurement group_id="O3" value="10.5" spread="38.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Hematocrit.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Hematocrit.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0269"/>
                    <measurement group_id="O2" value="-0.003" spread="0.0260"/>
                    <measurement group_id="O3" value="-0.003" spread="0.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Erythrocytes, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Erythrocytes.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocytes, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Erythrocytes.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.2922"/>
                    <measurement group_id="O2" value="-0.054" spread="0.2614"/>
                    <measurement group_id="O3" value="-0.031" spread="0.2776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin, Full Analysis Set</title>
        <description>Change from baseline in hematologic lab parameter of Hemoglobin.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin, Full Analysis Set</title>
          <description>Change from baseline in hematologic lab parameter of Hemoglobin.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="8.92"/>
                    <measurement group_id="O2" value="1.2" spread="8.37"/>
                    <measurement group_id="O3" value="1.9" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set</title>
        <description>Change from baseline in chemistry test ALT.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set</title>
          <description>Change from baseline in chemistry test ALT.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>ukat/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.2060"/>
                    <measurement group_id="O2" value="0.004" spread="0.2118"/>
                    <measurement group_id="O3" value="0.005" spread="0.2086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set</title>
        <description>Change from baseline in chemistry test AST.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set</title>
          <description>Change from baseline in chemistry test AST.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>ukat/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.1258"/>
                    <measurement group_id="O2" value="-0.018" spread="0.1280"/>
                    <measurement group_id="O3" value="-0.020" spread="0.1267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bilirubin, Full Analysis Set</title>
        <description>Change from baseline in chemistry test Bilirubin.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bilirubin, Full Analysis Set</title>
          <description>Change from baseline in chemistry test Bilirubin.</description>
          <population>Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.451" spread="3.0980"/>
                    <measurement group_id="O2" value="-0.297" spread="3.3972"/>
                    <measurement group_id="O3" value="-0.374" spread="3.2486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Asthma Exacerbations During Study Period</title>
        <description>Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit</description>
        <time_frame>From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented.</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Asthma Exacerbations During Study Period</title>
          <description>Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit</description>
          <population>Full analysis set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period</title>
        <description>Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma</description>
        <time_frame>From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented.</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period</title>
          <description>Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma</description>
          <population>Full analysis set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Blood Eosinophils Count</title>
        <description>Change from Baseline to End of Treatment in blood eosinophils count.</description>
        <time_frame>From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Blood Eosinophils Count</title>
          <description>Change from Baseline to End of Treatment in blood eosinophils count.</description>
          <population>Full analysis set.</population>
          <units>cell/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="50.24"/>
                    <measurement group_id="O2" value="-12.9" spread="212.51"/>
                    <measurement group_id="O3" value="-0.5" spread="155.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study</title>
        <description>Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study</description>
        <time_frame>From week 0 to week 184 in study treatment period and plus 12 weeks follow up period</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study</title>
          <description>Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study</description>
          <population>Full analysis set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at any visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both baseline and post-baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only post-baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Persistently Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Transiently Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="429"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="221"/>
                    <count group_id="O3" value="434"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="225"/>
                    <count group_id="O3" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb positive in ADA positive participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Exposure</title>
        <description>Duration of exposure</description>
        <time_frame>From week 0 to week 184 in study treatment period</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Benra 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benra 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>sum per row</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Exposure</title>
          <description>Duration of exposure</description>
          <population>Full analysis set.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.35" spread="10.112"/>
                    <measurement group_id="O2" value="25.36" spread="9.939"/>
                    <measurement group_id="O3" value="25.85" spread="10.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All participants completed treatment period up to Week 184.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Benra 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Benra 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Femoral hernia incarcerated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Musculoskeletal complication associated with device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ligament laxity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Silicon granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Polyarteritis nodosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="220"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="220"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="126" subjects_affected="67" subjects_at_risk="220"/>
                <counts group_id="E2" events="112" subjects_affected="64" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="220"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="220"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="56" subjects_affected="32" subjects_at_risk="220"/>
                <counts group_id="E2" events="41" subjects_affected="21" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="220"/>
                <counts group_id="E2" events="40" subjects_affected="20" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E2" events="31" subjects_affected="24" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All participants in this study had to complete treatment in predecessor studies. Therefore selection bias may exist. Baseline is defined for this study's entry value, not the value prior to Benralizumab treatment. All participants have been treated with Benralizumab prior to this study's entry.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>AstraZeneca Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 8002369933</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

